PUBLISHER: The Insight Partners | PRODUCT CODE: 1871466
PUBLISHER: The Insight Partners | PRODUCT CODE: 1871466
The Asia Pacific positive airway pressure (PAP) devices market is projected to grow significantly, reaching approximately US$ 2,394.30 million by 2031, up from US$ 1,341.04 million in 2023, with a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2023 to 2031.
Executive Summary and Market Analysis
The Asia Pacific PAP devices market is categorized into several regions, including China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The growth of this market is driven by several factors, including an aging population, an increasing number of patients with obstructive sleep apnea (OSA), advancements in PAP technology, a rise in chronic obstructive pulmonary disease (COPD) cases, and a trend towards home healthcare.
Market Segmentation Analysis
The Asia Pacific PAP devices market can be segmented based on product type, application, and end user:
Market Outlook
There is a growing preference among patients for receiving treatment in the comfort of their homes rather than in clinical settings. PAP devices are particularly effective in home care environments for managing sleep apnea and other respiratory conditions, which alleviates pressure on healthcare facilities and encourages regular use of these devices. Given that conditions like sleep apnea often require long-term treatment, PAP devices that facilitate at-home care are seen as cost-effective solutions.
The shift towards home healthcare is a significant driver for the sales of PAP devices designed for home use. Manufacturers are increasingly focusing on creating user-friendly, portable, and efficient devices to cater to this expanding market. For instance, ResMed has developed the AirMini Portable CPAP, which is tailored for home care, thereby influencing market dynamics through innovation and enhancing access to respiratory care in both developed and developing regions. As healthcare systems continue to prioritize home-based treatment options, this trend is expected to persist.
Country Insights
The Asia Pacific PAP devices market is comprised of several key countries, with China leading the market share in 2023. The growth in China can be attributed to a rise in new product approvals, a growing elderly population susceptible to sleep apnea, and an increase in respiratory diseases. China, with a GDP of US$ 18 trillion, represents 18% of the global economy, and healthcare spending constitutes 7.1% of its GDP. According to the China Macro Economy Journal 2021, around 264 million individuals aged over 60 years make up 18.7% of the population, contributing to a significant burden of respiratory diseases. A national survey indicated that China accounts for approximately 25% of global COPD cases, with a 67% increase in prevalence among individuals aged 40 and above over the past decade. Additionally, asthma poses a considerable public health challenge, with a prevalence rate of 4.2%, affecting around 45.7 million people in 2019, further driving the demand for PAP devices.
Company Profiles
Key players in the PAP devices market include ICU Medical Inc, React Health (formerly 3B Medical, Inc), Fisher & Paykel Healthcare Corp Ltd, BPL Medical Technologies Pvt Ltd, Koninklijke Philips NV, Dragerwerk AG & Co KGaA, ResMed Inc, Vyaire Medical Inc, Wellell Inc, Armstrong Medical Ltd, Lowenstein Medical UK Ltd, BMC Medical Co Ltd, and Narang Medical Limited, among others. These companies are employing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase market share.